Search Videos and More
ESMO26: Toni Choueiri, MD, on KEYNOTE-564
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.ESMO26: Toni Choueiri, MD on LITESPARK-012
Surprising results in first triplet combination study in advanced kidney cancer presented by Toni Choueiri, MD, at #ESMO26. Dr. Choueiri says even though the combination did not improve efficacy, the findings are important for informing future studies.ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer
Vincent (Wenxin) Xu, MD , shows among patients with advanced kidney cancer on immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors, while no KIM-1 drop was linked to immune-depleted tumors.FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science
When patients with bladder cancer complete treatment that is intended to cure the cancer, they may be left wondering if there is anything else they should do to keep the cancer from coming back.2026 ASCO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updatesASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.2026 ASCO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates2026 AACR Renal Cell Carcinoma Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.2026 AACR Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.2026 AACR Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.